Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|mTor Protein
Interventions: DRUG: Tamoxifen|DRUG: Everolimus
Sponsor: ARCAGY/ GINECO GROUP
Collaborators: Novartis